UNOS T1/T2 肝细胞癌经动脉放射栓塞可省略肺分流评估
该回顾性研究纳入 2004—2018 年接受钇-90 经动脉放射栓塞的早期肝细胞癌(UNOS T1/T2/Milan 标准)患者 448 例,分析术前 Tc-99m 大聚合白蛋白扫描测得的肺分流分数(LSF)。中位 LSF 为 3.9%,无 TIPS 者中位 LSF 为 3.8%;TIPS 与 LSF>10% 独立相关(OR 12.2)。作者提出,对无 TIPS 且计划行段性注射的 UNOS T1/T2 患者可省略 MAA 扫描。
要点
- UNOS T1/T2 且无 TIPS 的肝细胞癌患者 LSF 临床可忽略,中位 3.8%。
- TIPS 是 LSF>10% 的强相关因素(OR 12.2,95%CI 5.2-28.6)。
- 计划段性注射的无 TIPS 早期患者可考虑省略 MAA 肺分流评估。
核心结论
- 无 TIPS 的 UNOS T1/T2 肝细胞癌患者 LSF 临床可忽略,计划段性注射时可省略 MAA 肺分流评估。
研究设计与样本
- 回顾性分析 2004—2018 年接受钇-90 经动脉放射栓塞的肝细胞癌患者,纳入早期 HCC(UNOS T1/T2/Milan 标准)448 例。
- 所有患者均通过 Tc-99m 大聚合白蛋白扫描测定 LSF,并分析 LSF 与基线特征的关系。
主要发现
- 448 例中位年龄 65.6 岁,男性 303 例(68%),孤立病灶 352 例(79%),单叶病变 406 例(91%)。
- 中位 LSF 为 3.9%(IQR 2.4-6%),中位给药活度 0.9 GBq(IQR 0.6-1.4),中位段体积 170 cm3(范围 60-530),中位肺剂量 1.9 Gy(IQR 1.0-3.3)。
- TIPS 存在(n=38)与 LSF>10% 相关(OR 12.2;95%CI 5.2-28.6;p<0.001)。
- 无 TIPS 者中位 LSF 为 3.8%(IQR 2.4-5.7%),TIPS 者为 6%(IQR 3.8-15.3%),p<0.001。
临床怎么用
- 对无 TIPS 且计划行段性注射的 UNOS T1/T2 肝细胞癌患者,可省略术前 MAA 肺分流评估,以减少治疗等待时间、操作次数并方便远途患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Pre-treatment Tc-99m macroaggregated albumin (MAA) scans are routinely performed prior to transarterial radioembolization (TARE) to estimate lung shunt fraction (LSF) and lung dose. In this study, we investigate LSF observed in early hepatocellular carcinoma (HCC) and provide the scientific rationale for eliminating this step from routine practice. METHODS: Patients with HCC who underwent Y90 from 2004 to 2018 were reviewed. Inclusion criteria were early stage HCC (UNOS T1/T2/Milan criteria: solitary ≤5 cm, 3 nodules ≤3 cm). LSF was determined using MAA in all patients. Associations between LSF and baseline characteristics were investigated. A "no-MAA" paradigm was then proposed based on a homogenous group that expressed very low LSF. RESULTS: Of 1,175 patients with HCC treated with TARE, 448 patients met inclusion criteria. Mean age was 65.6 years and 303 (68%) were males. A total of 352 (79%) had solitary lesions and 406 (91%) unilobar disease. Two-hundred and forty-three (54%), 178 (40%) and 27 (6%) patients were Child-Pugh class A, B and C, respectively. Median LSF was 3.9% (IQR 2.4-6%). Median administered activity was 0.9 GBq (IQR 0.6-1.4), for a median segmental volume of 170 cm3 (range: 60-530). Median lung dose was 1.9 Gy (IQR: 1.0-3.3). The presence of a transjugular intrahepatic portosystemic shunt (TIPS; n = 38) was associated with LSF >10% (odds ratio 12.2; 95% CI 5.2-28.6; p <0.001). Median LSF was 3.8% (IQR: 2.4-5.7%) and 6% (IQR: 3.8-15.3%) in no-TIPS vs. TIPS patients (p <0.001). CONCLUSION: LSF is clinically negligible in patients with UNOS T1/T2 HCC without TIPS. When segmental injections are planned, this step can be eliminated, thereby reducing time-to-treatment, number of procedures, and improving convenience for patients traveling from faraway. LAY SUMMARY: Transarterial radioembolization is a microembolic transarterial treatment for hepatocellular carcinoma. In our study, we found that early stage patients, where segmental injections are planned, exhibited low lung shunting, effectively eliminating the risk of radiation pneumonitis. We propose that the lung shunt study be eliminated in this subgroup, thus leading to fewer procedures, a cost reduction and improved convenience for patients.
引用
- Gabr A, Ranganathan S, Mouli SK, et al. Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation. J Hepatol. 2020. PMID: 32145255. doi:10.1016/j.jhep.2020.02.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。